Biophytis received a deficiency notice from The Nasdaq Stock Market stating that the company has not filed its financial information for the six-month period ended June 30, 2022 on a Form 6-K and as a result the company no longer complies with Nasdaq’s listing rules for continued listing set forth in the Listing Rule 5250(c)(2). The company is currently working on the Plan to regain compliance with respect to the Listing Rule 5250(c)(2) to meet the requirements for continued listing on the Nasdaq Capital Market. It intends to submit such Plan to Nasdaq as soon as practicable prior to March 6.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
